Potential to become new standard of care for moderate-to-severe DED and a new blockbuster drug for China
Zhaoke Ophthalmology has announced that the Phase III clinical trial of one of the company's core drug candidates, Cyclosporine A (CsA) Ophthalmic Gel for the treatment of Dry Eye Disease (DED) has met its primary endpoint in inferior fluorescein corneal staining score (ICSS). ...
If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.
Accordingly, you can do the same with others as well.